Free Trial
NASDAQ:TRDA

Entrada Therapeutics Q2 2025 Earnings Report

Entrada Therapeutics logo
$5.30 -0.65 (-10.92%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$5.30 0.00 (-0.09%)
As of 08/7/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Entrada Therapeutics EPS Results

Actual EPS
-$1.04
Consensus EPS
-$0.86
Beat/Miss
Missed by -$0.18
One Year Ago EPS
N/A

Entrada Therapeutics Revenue Results

Actual Revenue
$1.98 million
Expected Revenue
$8.17 million
Beat/Miss
Missed by -$6.19 million
YoY Revenue Growth
N/A

Entrada Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Entrada Therapeutics' Q3 2025 earnings is scheduled for Tuesday, August 12, 2025

Entrada Therapeutics Earnings Headlines

GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.
See More Entrada Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Entrada Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entrada Therapeutics and other key companies, straight to your email.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ:TRDA), a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

View Entrada Therapeutics Profile

More Earnings Resources from MarketBeat